About Vaxcyte, Inc.
https://vaxcyte.comVaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia.
CEO
Grant E. Pickering
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 161
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:13.1M
Value:$635.68M
FMR LLC
Shares:12.51M
Value:$606.86M
VANGUARD GROUP INC
Shares:12.32M
Value:$597.67M
Summary
Showing Top 3 of 321
About Vaxcyte, Inc.
https://vaxcyte.comVaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $242.38M ▲ | $-212.83M ▼ | 0% | $-1.56 ▼ | $-209.77M ▼ |
| Q2-2025 | $0 | $221.23M ▲ | $-166.57M ▼ | 0% | $-1.22 ▼ | $-161.58M ▲ |
| Q1-2025 | $0 | $180.79M ▲ | $-140.72M ▼ | 0% | $-1.04 ▲ | $-175.92M ▼ |
| Q4-2024 | $0 | $162.17M ▲ | $-137.08M ▼ | 0% | $-1.12 ▼ | $-52.58M ▲ |
| Q3-2024 | $0 | $139.92M | $-103.12M | 0% | $-0.83 | $-135.14M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.71B ▲ | $3.17B ▼ | $278.72M ▲ | $2.89B ▼ |
| Q2-2025 | $1.66B ▼ | $3.31B ▼ | $234.03M ▲ | $3.07B ▼ |
| Q1-2025 | $1.67B ▼ | $3.38B ▼ | $178.08M ▼ | $3.2B ▼ |
| Q4-2024 | $1.75B ▼ | $3.51B ▼ | $205.5M ▲ | $3.31B ▼ |
| Q3-2024 | $2.18B | $3.56B | $142.11M | $3.42B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-212.83M ▼ | $-143.31M ▼ | $121.17M ▲ | $-3.67M ▼ | $-25.52M ▲ | $-155.35M ▼ |
| Q2-2025 | $-166.57M ▼ | $-121.17M ▲ | $77.74M ▼ | $2.52M ▲ | $-40.11M ▲ | $-101.65M ▲ |
| Q1-2025 | $-140.72M ▼ | $-166.27M ▼ | $123.32M ▲ | $759K ▼ | $-41.03M ▲ | $-193.03M ▼ |
| Q4-2024 | $-137.08M ▼ | $-111.4M ▼ | $-557.17M ▲ | $4.91M ▼ | $-662.31M ▼ | $-141.43M ▼ |
| Q3-2024 | $-103.12M | $-60.71M | $-917.02M | $1.52B | $531.73M | $-98.79M |
Revenue by Products
| Product | Q3-2021 | Q4-2021 | Q1-2022 | Q2-2022 |
|---|---|---|---|---|
 Pneumococcal Conjugate Vaccine | $7.00Bn ▲ | $0 ▼ | $7.00Bn ▲ | $7.00Bn ▲ |
CEO
Grant E. Pickering
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 161
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:13.1M
Value:$635.68M
FMR LLC
Shares:12.51M
Value:$606.86M
VANGUARD GROUP INC
Shares:12.32M
Value:$597.67M
Summary
Showing Top 3 of 321